Meet India’s Self-Made Biologics Brewmaster Billionaire https://t.co/YiOguteUzQ https://t.co/YiOguteUzQ ...

Key Takeaways CAPR's BLA for deramiocel in DMD cardiomyopathy received an FDA complete response letter. The FDA cited a lack of substantial evidence and unresolved CMC issues in the BLA. CAPR plans talks with the FDA to clarify issues and chart a regulatory path for deramiocel.Shares of Capricor Therapeutics (CAPR) tanked 33% on Friday after it announced that the FDA issued a complete response letter (“CRL”) to the biologics license application (“BLA”) seeking approval for cell therapy deramiocel, to trea ...

If I were to ask you what are the trace attributes of an effective leader, what are the words that come to your mind. Is it confidence, charisma, boldness, decisiveness. You know the leaders that we admire who are empowering, motivating, they can rally the masses. You know the leaders who seem to run on endless fuel and energy, the extroverted leaders.I think we can all agree those are traits and attributes of an effective leader. But what if I flipped the script. What if I flipped the 105year-old script.Sc ...

[Music] The moment we adopt blindly adopt a religion or a political system or literary dogma become automatons. This was said by Ana Nin who is a French essayist. I'm Sundam and today I'm going to talk about a very deep a very deeply intriguing and important aspect of human nature.The rationality of human reasoning. Now this sounds a bit conducting isn't it. I mean reasoning is basically rationality and the rationality of human rationality doesn't make much sense.It's paradoxical. While we humans like to th ...

全球政策进展 | 海南 【SynBioCon】 获 悉，近日，海南省 工业和信息化厅近日牵头联合省发展改革委、省科学技术厅 制定出台了 《海南省推动生物制造产业高质量发展行动方案（2025-2027年）》 。（以下简称《行 动方案》）。 四是产业基础优势 ，海南在高端食品加工、生物医药、全生物降解材料等产业产值规模已近800亿 元，有了比较好的产业基础。 未来，海南将发展 海洋生物基材料 ， 利用蓝藻、红藻等海洋资源制造聚乳酸、卡拉胶 纤维等材 料 。在儋州、海口等地建设海洋生物制造中试孵化平台，丰富涉及 功能食品、日化品、微生物制剂 等行业中海洋生物制造产品的种类。"黄家林说。 《行动方案》也将成为海南省发展生物制造产业的领头文件，推进 产业向新提质增效。 《行动方案》结合海南省资源禀赋、产业发展基础、区位自然条件、自贸港政策制度优势等提出了未 来三年 "5+8+N" 发展路径，即聚焦"海洋生物制造、生物育种"两大特色创新。 未来，海南将重点在" 生物医药、生物食品、生物农业、生物材料、生物化工与能源"五大领域 发 力；围绕"技术创新-成果转化-企业培育-产业发展"主线，实施"高能级创新平台体系构建、因地制 ...

China faces significant challenges advancing its semiconductor lithography, a key hurdle for its drive toward technological self-sufficiency and superiority in the trade war with the US https://t.co/c7HnFK89mM ...

The digital economy as we know it was born out of post Cold-War optimism and globalization. Liberal democracy would continue to spread. Governments and companies were accustomed to global market access and frictionless trade. The likes of Google and Facebook were born out of the belief that borderless innovation and limited interference by governments were preordained. But rather than a new normal of uninterrupted globalization destined to continue forever, the book argues that this period of globalization ...

Group 1 - The article discusses the challenges of investing in bonds and small-cap stocks in 2025, highlighting a lingering attachment to actively managed funds despite past performance issues [1] - It emphasizes the historical context of fund fees exceeding 1% while yielding an average return of only 2% per year, raising questions about the value of active management [1] - The initiative aims to provide in-depth analysis of the asset management market dynamics, combining data analysis with actionable insights on ETFs and trending instruments [1] Group 2 - The author, Tommaso Scarpellini, is identified as a seasoned financial researcher with experience in banking and financial analytics, contributing to the credibility of the analysis [1] - The mission of the initiative is to deliver valuable, data-driven perspectives to assist investors in making informed decisions in a rapidly changing market [1]

Summary of Capricor Therapeutics (CAPR) Update Call Company Overview - **Company**: Capricor Therapeutics - **Focus**: Development of Daramyacel, a cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) Key Points Regulatory Update - Capricor received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for Daramyacel, indicating that the application does not meet the requirements for substantial evidence of effectiveness and requires more clinical data [4][5] - The review clock has been stopped until a complete response is submitted, and Capricor does not believe a new BLA will be required [5][41] - Capricor is preparing a written response to the CRL and has initiated engagement with the FDA for further discussions [5][10] Clinical Data and Efficacy - The BLA was supported by data from the HOPE-two trial, which demonstrated statistically significant benefits in cardiac function [7][8] - The HOPE-two open label extension study showed significant results in left ventricular ejection fraction with a p-value of 0.0079 [9] - Ongoing Phase III HOPE-three clinical trial is seen as a key opportunity to address the FDA's request for additional clinical data [10] - HOPE-three has completed a twelve-month evaluation of 104 DMD patients, with data expected in Q3 2025 [10] Manufacturing and Quality Control - Capricor is committed to resolving outstanding issues in the chemistry, manufacturing, and controls (CMC) section of the application [11] - The company believes that the issues raised by the FDA are resolvable in a timely manner [11] Industry Context - The FDA's decision is viewed as concerning, especially given the high unmet medical need in DMD and the innovative nature of the therapy [6][12] - Capricor emphasizes the importance of using long-term extension data and real-world evidence in evaluating therapies for rare diseases like DMD [12] Support from Medical Community - A group of leading DMD physician scientists submitted a letter to the FDA expressing support for the Daramyacel clinical program [13] - The letter highlighted their extensive experience in treating DMD and their belief in the efficacy and safety of Daramyacel [13] Future Outlook - Capricor remains committed to working collaboratively with the FDA and is optimistic about the potential for Daramyacel to receive approval [14][15] - The company aims to provide updates as they achieve clarity with the FDA regarding the path forward [69] Financial and Strategic Considerations - Capricor maintains its priority review status and is focused on addressing the FDA's concerns without needing a new BLA [48] - The partnership with NS Pharma remains strong, with continued commitment to commercialization in the U.S. despite the CRL setback [58] Additional Insights - The FDA's cancellation of the Public Advisory Committee meeting without explanation raised concerns about the review process [6] - Capricor's approach to statistical analysis in clinical trials has been a point of contention with the FDA, particularly regarding the use of parametric versus nonparametric models [30][36] This summary encapsulates the critical updates and insights from the Capricor Therapeutics conference call, highlighting the company's current challenges and future strategies in the context of regulatory approval for Daramyacel.

Company Overview - Tevogen Bio Holdings Inc. has officially opened its newly expanded corporate headquarters in Warren, New Jersey, which was fully funded by the CEO, Ryan Saadi, resulting in no costs to the company or its shareholders [2][6]. Facility Expansion - The new facility has been completed ahead of schedule and more than doubles the previous footprint of Tevogen, allowing for the centralization of research, regulatory affairs, and the expanding Tevogen.AI teams under one roof [3][6]. Future Plans - A formal ribbon-cutting ceremony is planned to celebrate the new headquarters, which will include local officials, employees, and community partners [3].